Latest news with #Mycamine
News18
2 days ago
- Health
- News18
Glenmark to launch injection to treat fungal infections in US
Agency: Last Updated: New Delhi, Aug 19 (PTI) Glenmark Pharmaceuticals Inc., USA on Tuesday said it will launch Micafungin for injection, used to treat fungal infections, in the US market. Micafungin for injection will be launched in strengths of 50 mg/vial and 100 mg/vial in a single dose, the company said in a statement. The company will begin distribution in September 2025, it added. The launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (single-dose vial) will grow the company's portfolio of products within the institutional channel, while also strengthening its commitment to bring quality and affordable alternatives to market for patients in need, Glenmark President & Business Head, North America Marc Kikuchi said. Glenmark's Micafungin for Injection 50 mg/vial and 100 mg/vial in single dose is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine for injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. Citing IQVIA sales data for the 12-month period ended June 2025, the company said the Mycamine ® for Injection, 50 mg/vial and 100 mg/vial, market achieved annual sales of approximately USD 60.7 million. PTI RKL SHW view comments First Published: August 19, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
Business Standard
2 days ago
- Business
- Business Standard
Glenmark USA to launch Micafungin for Injection 50 mg/vial and 100 mg/vial
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA - 021506 and the company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million*.
